Geraniol rescues inflammation in cellular and animal models of mevalonate kinase deficiency

In Vivo

Volumn 25, Issue 1, 2011, Pages 87-92

  Marcuzzi, Annalisa ^a   Crovella, Sergio ^a,b   Pontillo, Alessandra ^a  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Geraniol; Inflammation; Mevalonate kinase deficiency; Pamidronate

Indexed keywords

CHOLESTEROL; GERANIOL; INTERLEUKIN 1BETA; MEVALONATE KINASE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MEVALONATE KINASE DEFICIENCY; MONOCYTE; MOUSE; NONHUMAN;

EID: 79952027845     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Halasy-Nagy JM, Rodan GA and Reszka AA: Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29: 553-559, 2001. (Pubitemid 33124298)
2. Russell RG, Watts NB, Ebetino FH and Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19: 733-759, 2008.
3. Diaz-Borjon A, Seyler TM, Chen NL and Lim SS: Bisphosphonate-associated arthritis. J Clin Rheumatol 12: 131-133, 2006.
4. Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J and Ibarra de Palacios P: An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61: 386-392, 1997.
5. De Leo L, Marcuzzi A, Decorti G, Tommasini A, Crovella S and Pontillo A: Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: In vitro and in vivo approaches. Pharmacol Res 61: 506-511, 2010.
6. Mandey SH, Kuijk LM, Frenkel J and Waterham HR: A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 54: 3690-3695, 2006.
7. Dombrecht EJ, Schuerwegh AJ, Bridts CH, Ebo DG, Van Offel JF, Stevens WJ and De Clerck LS: Effect of bisphosphonates on nitric oxide production by inflammatory activated chondrocytes. Clin Exp Rheumatol 25: 817-822, 2007. (Pubitemid 351166431)
8. Deng X, Yu Z, Funayama H, Shoji N, Sasano T, Iwakura Y, Sugawara S and Endo Y: Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. Toxicol Appl Pharmacol 213: 64-73, 2006.
9. Marcuzzi A, Pontillo A, De Leo L, Tommasini A, Decorti G, Not T and Ventura A: Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency. Pediatr Res 64: 177-182, 2008.
10. Houten SM, Wanders RJ and Waterham HR: Biochemical and genetic aspects of mevalonate kinase and its deficiency. Biochim Biophys Acta 1529: 19-32, 2000.
11. Frenkel J, Rijkers GT, Mandey SH, Buurman SW, Houten SM, Wanders RJ, Waterham HR and Kuis W: Lack of isoprenoid products raises ex vivo interleukin-lbeta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 46: 2794-2803, 2002.
12. Kuijk LM, Mandey SH, Schellens I, Waterham HR, Rijkers GT, Coffer PJ and Frenkel J: Statin synergizes with LPS to induce IL-1 beta release by THP-1 cells through activation of caspase-1. Mol Immunol 45: 2158-2165, 2008.
13. Marcuzzi A, Tommasini A, Crovella S and Pontillo A: Natural isoprenoids inhibit LPS induced-production of cytokines and nitric oxide in aminobisphosphonate-treated monocytes. Int Immunopharmacol 61: 506-510, 2010.
14. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
15. Slobodin G, Rosner I, Feld J, Rimar D, Rozenbaum M, Boulman N and Odeh M: Pamidronate treatment in rheumatology practice: a comprehensive review. Clin Rheumatol 28: 1359-1364, 2009.
16. Cecchini MG and Fleisch H: Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 5: 1019-1027, 1990.
17. Pennanen N, Lapinjoki S, Urtti A and Monkkonen J: Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 12: 916-922, 1995.
18. Van Offel JF, Schuerwegh AJ, Bridts CH, Bracke PG, Stevens WJ and De Clerck LS: Influence of cyclic intravenous Pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clin Exp Rheumatol 19: 13-20, 2001. (Pubitemid 32203841)
19. Carbone LD, Warrington KJ, Barrow KD, Pugazhenthi M, Watsky MA, Somes G, Ingels J and Postlethwaite AE: Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol 146: 371-380, 2006. (Pubitemid 44722154)
20. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242, 2001.
21. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW and Papapoulos SE: Differentiating the mechanisms of antiresorptive action of nitrogen-containing bisphosphonates. Bone 33: 805-811, 2003.
22. Reinholz GG, Getz B, Sanders ES, Karpeisky MY, Padyukova N, Mikhailov SN, Ingle JN and Spelsberg TC: Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Res Treat 71: 257-268, 2002. (Pubitemid 34263989)
23. Suri S, Monkkonen J, Taskinen M, Pesonen J, Blank MA, Phipps RJ and Rogers MJ: Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 29: 336-343, 2001.
24. Marcuzzi A, Decorti G, Pontillo A, Ventura A and Tommasini A: Decreased cholesterol levels reflect a consumption of antiinflammatory isoprenoids associated with an impaired control of inflammation in a mouse model of mevalonate kinase deficiency. Inflamm Res 59: 335-338, 2010.